Growth Through Acquisition Profounda was recently acquired by Maxygen, Inc., highlighting an expansion strategy that could open opportunities for collaborative product development, licensing, or integration with their broader portfolio in the pharmaceutical industry.

Innovative Product Launches The company has demonstrated an ability to introduce new products such as Rhinase Nasal Mist and Gel, suggesting a focus on market innovation and potential needs for manufacturing scale-up, packaging, and distribution services.

Market Focus Profounda’s emphasis on both generic and branded pharmaceutical products indicates opportunities for suppliers in formulation development, regulatory consulting, and packaging solutions tailored to differentiated markets.

Technology Usage Utilizing a diverse tech stack including web development and security tools points to a strategic digital presence, implying potential for tech partnerships related to eCommerce, digital marketing, or clinical data management.

Financial Profile With annual revenues estimated between $10M and $25M and a small team, Profounda represents a mid-sized, agile company that could be receptive to strategic partnerships in manufacturing, distribution, or R&D service scaling to foster growth.